|
Name |
Tridecane
|
Molecular Formula | C13H28 | |
IUPAC Name* |
tridecane
|
|
SMILES |
CCCCCCCCCCCCC
|
|
InChI |
InChI=1S/C13H28/c1-3-5-7-9-11-13-12-10-8-6-4-2/h3-13H2,1-2H3
|
|
InChIKey |
IIYFAKIEWZDVMP-UHFFFAOYSA-N
|
|
Synonyms |
Tridecane; N-TRIDECANE; 629-50-5; Tridekan; Dodecane, methyl-; TRIDECANE, N-; A3LZF0L939; CHEBI:35998; NSC-66205; TRD; Tridecane, analytical standard; HSDB 5727; EINECS 211-093-4; NSC 66205; tridecan; UNII-A3LZF0L939; MFCD00008979; Tridecane, >=99%; Tridecane, 99.0%; TRIDECANE [INCI]; DSSTox_CID_7266; EC 211-093-4; N-TRIDECANE [HSDB]; DSSTox_RID_78377; Tridecane_GurudeebanSatyavani; DSSTox_GSID_27266; CHEMBL135694; DTXSID6027266; Tridecane-multiple sizes available; CH3-[CH2]11-CH3; NSC66205; ZINC1693738; Tox21_303043; LMFA11000001; STL301147; AKOS016011009; HY-W088037; NCGC00257175-01; CAS-629-50-5; LS-14257; DB-054344; CS-0128437; FT-0632663; T0411; Q150788; 757DB156-6441-49B0-A824-1532074AC0F6
|
|
CAS | 629-50-5 | |
PubChem CID | 12388 | |
ChEMBL ID | CHEMBL135694 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 184.36 | ALogp: | 6.6 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 13 | QED Weighted: | 0.389 |
Caco-2 Permeability: | -4.607 | MDCK Permeability: | 0.00001090 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.553 |
30% Bioavailability (F30%): | 0.997 |
Blood-Brain-Barrier Penetration (BBB): | 0.296 | Plasma Protein Binding (PPB): | 97.87% |
Volume Distribution (VD): | 3.46 | Fu: | 1.82% |
CYP1A2-inhibitor: | 0.711 | CYP1A2-substrate: | 0.213 |
CYP2C19-inhibitor: | 0.521 | CYP2C19-substrate: | 0.183 |
CYP2C9-inhibitor: | 0.197 | CYP2C9-substrate: | 0.934 |
CYP2D6-inhibitor: | 0.14 | CYP2D6-substrate: | 0.08 |
CYP3A4-inhibitor: | 0.194 | CYP3A4-substrate: | 0.066 |
Clearance (CL): | 4.807 | Half-life (T1/2): | 0.118 |
hERG Blockers: | 0.169 | Human Hepatotoxicity (H-HT): | 0.01 |
Drug-inuced Liver Injury (DILI): | 0.177 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.045 | Maximum Recommended Daily Dose: | 0.027 |
Skin Sensitization: | 0.936 | Carcinogencity: | 0.045 |
Eye Corrosion: | 0.994 | Eye Irritation: | 0.957 |
Respiratory Toxicity: | 0.562 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000422 | 0.925 | D05ATI | 0.615 | ||||
ENC000272 | 0.919 | D0Z5SM | 0.542 | ||||
ENC000423 | 0.860 | D07ILQ | 0.492 | ||||
ENC000473 | 0.838 | D00AOJ | 0.444 | ||||
ENC000379 | 0.804 | D05QNO | 0.441 | ||||
ENC000327 | 0.762 | D0O1PH | 0.431 | ||||
ENC000276 | 0.762 | D00FGR | 0.418 | ||||
ENC000493 | 0.757 | D0Y8DP | 0.393 | ||||
ENC000427 | 0.755 | D0T9TJ | 0.378 | ||||
ENC000266 | 0.717 | D00MLW | 0.375 |